| Alexandru Mihai Vaida, MD | |
|
246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301-2548 | |
| (603) 224-1725 | |
| (603) 227-7557 |
| Full Name | Alexandru Mihai Vaida |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 29 Years |
| Location | 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285703124 | NPI | - | NPPES |
| 35088857 | Other | OH | LICENSE |
| 000000423375 | Other | OH | ANTHEM |
| 000000626785 | Other | OH | ANTHEM |
| 23936 | Other | WV | WV LICENSE |
| P00782451 | Other | OH | RRMCR |
| 2697694 | Medicaid | OH | |
| 3810008746 | Medicaid | WV |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Lakes Region General Hospital | Laconia, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Hospital Inc | 6103721790 | 462 |
News Archive
DFine, Inc., developer of minimally invasive solutions for treating vertebral pathologies, announced today the closing of a $36.2 million round of equity financing. The round was led by new investor Split Rock Partners. Funding was also contributed by new investor OrbiMed, and inside investors Prospect Venture Partners, Vanguard Ventures, BBT Fund/Apothecary Capital, Highland Capital Management and several private investors.
MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.
OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.
Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
› Verified 2 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
DFine, Inc., developer of minimally invasive solutions for treating vertebral pathologies, announced today the closing of a $36.2 million round of equity financing. The round was led by new investor Split Rock Partners. Funding was also contributed by new investor OrbiMed, and inside investors Prospect Venture Partners, Vanguard Ventures, BBT Fund/Apothecary Capital, Highland Capital Management and several private investors.
MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.
OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.
Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexandru Mihai Vaida, MD 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301-2548 Ph: (603) 224-1725 | Alexandru Mihai Vaida, MD 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301-2548 Ph: (603) 224-1725 |
News Archive
DFine, Inc., developer of minimally invasive solutions for treating vertebral pathologies, announced today the closing of a $36.2 million round of equity financing. The round was led by new investor Split Rock Partners. Funding was also contributed by new investor OrbiMed, and inside investors Prospect Venture Partners, Vanguard Ventures, BBT Fund/Apothecary Capital, Highland Capital Management and several private investors.
MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.
OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.
Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
› Verified 2 days ago
Louis Russo, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant St., Memorial Building, West, Ground Floor, Concord, NH 03301 Phone: 603-224-1725 Fax: 603-227-7557 | |
Dr. Nicola A Francalancia, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant St Ste 103, Concord, NH 03301 Phone: 603-224-1725 Fax: 603-227-7557 | |
Gerald L Sardella, MD FACS Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant St, Suite 103, Concord, NH 03301 Phone: 603-224-1725 Fax: 603-224-6094 |